Irritable Bowel Syndrome News

CHARLOTTE, N.C. — Treatment for irritable bowel syndrome with diarrhea should target bloating in addition to diarrhea and abdominal pain or discomfort, according to data presented at the ACG Annual Scientific Meeting.

CHARLOTTE, N.C. — Once daily plecanatide decreased symptom severity among patients with irritable bowel syndrome-constipation and severe abdominal pain and bloating, according to a poster presented at the ACG Annual Scientific Meeting.

CHARLOTTE, N.C. — An orally ingested vibrating capsule was found to be safe, well tolerated and easy to use for the treatment of chronic idiopathic constipation, according to data presented at the ACG Annual Scientific Meeting.

CHARLOTTE, N.C. — In a Healio video exclusive, Eamonn Quigley, MD, reported increased compliance to an orally ingested vibrating capsule predicted positive outcomes among patients with chronic idiopathic constipation.

In patients with autoimmune rheumatic diseases, vaccination against COVID-19 does not appear to correlate with increased flares, regardless of disease status, previous exposure and vaccine type, according to data published in Rheumatology.

CHARLOTTE, N.C. — A higher dose of upadacitinib decreased disease severity and induced clinical remission for a longer period among patients with active ulcerative colitis, according to a presenter at ACG Annual Scientific Meeting.

Virtual integrated care platform, GI OnDemand, has partnered with Mindset Health, a hypnotherapy mobile app, just days after announcing its partnership with Trellus Health, an inflammatory bowel disease management solution.

Particulate matter and toxic release exposure correlated with a higher incidence of irritable bowel syndrome among a subset of California residents, according to data published in Clinical Gastroenterology and Hepatology.

Transcutaneous electrical acustimulation improved abdominal pain and constipation symptoms in patients with irritable bowel syndrome compared with a sham procedure, according to a study published in American Journal of Gastroenterology.

Ironwood Pharmaceuticals Inc. announced positive results from its phase 3 trial that evaluated Linzess for the treatment of pediatric patients with functional constipation, according to a company press release.